-

AmerisourceBergen Completes Acquisition of PharmaLex

Acquisition advances role as a partner of choice for biopharmaceutical companies by enhancing global portfolio of specialty services

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) today announced the completion of its acquisition of PharmaLex Holding GmbH.

The acquisition of PharmaLex enhances AmerisourceBergen’s growth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services capabilities. PharmaLex’s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance services expand AmerisourceBergen’s role as partner of choice for biopharmaceutical partners across the pharmaceutical development and commercialization journey.

About AmerisourceBergen

AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our approximately 44,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at investor.amerisourcebergen.com.

Contacts

Investors:
Bennett S. Murphy
610-727-3693
bmurphy@amerisourcebergen.com

Media:
Lauren Esposito
215-460-6981
lesposito@amerisourcebergen.com

Industry:

AmerisourceBergen Corporation

NYSE:ABC
Release Versions
English

Contacts

Investors:
Bennett S. Murphy
610-727-3693
bmurphy@amerisourcebergen.com

Media:
Lauren Esposito
215-460-6981
lesposito@amerisourcebergen.com

More News From AmerisourceBergen Corporation

Cencora Announces Updated Fiscal Year 2026 Financial Outlook

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today updated its fiscal year 2026 financial guidance as a result of recent opportunistic share repurchases. Cencora now expects adjusted diluted earnings per share to be in the range of $17.70 to $17.90, up from the previous range of $17.65 to $17.90. The opportunistic share repurchases completed in May align with the Company’s previously disclosed expectation that it will repurchase $1.0 billion in shares of common stock by the end...

Cencora Reports Fiscal 2026 Second Quarter Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 second quarter ended March 31, 2026, revenue increased 3.8 percent year-over-year to $78.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $8.40 for the second quarter of fiscal 2026 compared to $3.68 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below,...

Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 6, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Fin...
Back to Newsroom